 Connection
Halis Akturk to Retrospective Studies
This is a "connection" page, showing publications Halis Akturk has written about Retrospective Studies.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.467 |
|
|
|
-
Akturk HK, Karakus KE, Chen B, Walker TC. Exploring the Relationship Between Newly Defined Continuous Glucose Monitoring (CGM) Metrics and the Standard CGM Metrics in 30,000 People with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):264-270.
Score: 0.066
-
Akturk HK, Karakus KE, Cengiz D, Mason E, Beck E, Kaur G, Garg SK. Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes. Diabetes Technol Ther. 2026 Mar; 28(3):193-200.
Score: 0.066
-
Karakus KE, Snell-Bergeon J, Mason E, Akturk HK. Improvement in Newly Defined Continuous Glucose Monitor Metrics, Extended Hypoglycemia, and Extended Hyperglycemia With Automated Insulin Delivery Initiation in Adults With Type 1 Diabetes. J Diabetes Sci Technol. 2026 May; 20(3):721-726.
Score: 0.060
-
Akturk HK, Dong F, Snell-Bergeon JK, Karakus KE, Shah VN. Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study. J Diabetes Sci Technol. 2025 Mar; 19(2):292-296.
Score: 0.057
-
Akturk HK, Dowd R, Shankar K, Derdzinski M. Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features. Diabetes Technol Ther. 2021 03; 23(S1):S21-S26.
Score: 0.046
-
Akturk HK, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes. Diabetes Technol Ther. 2021 01; 23(1):81-83.
Score: 0.044
-
Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020 04; 22(4):583-589.
Score: 0.043
-
Karakus KE, Clayton MG, Baschal EE, McDaniel KA, Yu L, Haider Z, Polsky S, Akturk HK, Gottlieb PA, Garg SK, Michels AW. Differences in Clinical Manifestations and Islet Autoantibodies by Age in Adult-Onset Type 1 Diabetes. Diabetes Care. 2026 07 01; 49(7):1194-1201.
Score: 0.017
-
Snell-Bergeon JK, Kaur G, Renner D, Akturk HK, Beatson C, Garg SK. Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 01; 27(1):1-9.
Score: 0.015
-
Garg SK, Akturk HK, Kaur G, Beatson C, Snell-Bergeon J. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024 06; 26(6):367-374.
Score: 0.014
-
Klein MP, Akturk HK, Snell-Bergeon JK, Shah VN. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity. J Diabetes Sci Technol. 2025 Mar; 19(2):297-303.
Score: 0.014
-
Shah VN, Kanapka LG, Akturk HK, Polsky S, Forlenza GP, Kollman C, Beck RW, Snell-Bergeon JK. Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study. Diabetes Technol Ther. 2024 04; 26(4):246-251.
Score: 0.014
-
Kaur H, Schneider N, Pyle L, Campbell K, Akturk HK, Shah VN. Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis. Diabetes Technol Ther. 2019 12; 21(12):736-739.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|